Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia, Myeloid, Acute 20Lung Neoplasms 19Burkitt Lymphoma 18Recurrence 14Lymphoma 14Hodgkin Disease 14Lymphoma, Non-Hodgkin 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Neuroblastoma 10Lymphoma, Mantle-Cell 10Lymphoma, B-Cell 10Leukemia 10Carcinoma, Non-Small-Cell Lung 10Medulloblastoma 8Neoplasms, Germ Cell and Embryonal 7Neoplasms 7Lymphoma, Follicular 7Multiple Myeloma 6Lymphoma, T-Cell 6Brain Neoplasms 6Sarcoma, Ewing 5Retinoblastoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Immunoblastic Lymphadenopathy 5Ependymoma 5Rhabdomyosarcoma 4Rhabdoid Tumor 4

Interventions

tislelizumab 1selinexor 1atezolizumab 1anlotinib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Cancer × Etoposide × 1 year × Clear all
NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
165 enrolled

Extensive Stage Lung Small Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡